• Popular
    • Medicine
    • Radiology
    • Cardiology
    • Surgery
    • Nanomedicine
    • Military Medicine
    • Rehab
  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS
  • Submit PR
  • Log in
Medgadget
Medgadget
  • Popular
    • Medicine
      Refillable Device for Drug Delivery Past the Blood-Brain Barrier: Interview with Mike Maglin, CEO at CraniUS

      Refillable Device for Drug Delivery Past the Blood-Brain Barrier: Interview with Mike Maglin, CEO at CraniUS

      Implantable Bioreactor for Kidney Cells

      Implantable Bioreactor for Kidney Cells

      Etched Nanopillars Kill Bacteria, Fungi on Titanium Implants

      Etched Nanopillars Kill Bacteria, Fungi on Titanium Implants

      Cells Release Insulin in Response to Music

      Cells Release Insulin in Response to Music

    • Radiology
      Ultrasound-Equipped Bra Monitors for Breast Cancer

      Ultrasound-Equipped Bra Monitors for Breast Cancer

      Portable and Radiation-Free Imaging with Magnetic Nanoparticles

      Portable and Radiation-Free Imaging with Magnetic Nanoparticles

      Imaging Technique Reveals Living Brain Tissue in its Complexity

      Imaging Technique Reveals Living Brain Tissue in its Complexity

      Wearable Ultrasound for Deep Tissue Monitoring

      Wearable Ultrasound for Deep Tissue Monitoring

    • Cardiology
      Ultrasound-Equipped Bra Monitors for Breast Cancer

      Ultrasound-Equipped Bra Monitors for Breast Cancer

      3D Printed Heart Muscle Beats

      3D Printed Heart Muscle Beats

      Wireless Patch Monitors, Paces Heart and then Biodegrades

      Wireless Patch Monitors, Paces Heart and then Biodegrades

      Photonic Radar Monitors Breathing from a Distance

      Photonic Radar Monitors Breathing from a Distance

    • Surgery
      Refillable Device for Drug Delivery Past the Blood-Brain Barrier: Interview with Mike Maglin, CEO at CraniUS

      Refillable Device for Drug Delivery Past the Blood-Brain Barrier: Interview with Mike Maglin, CEO at CraniUS

      Droplet Battery Harnesses Ionic Gradients for Bioelectronic Implants

      Droplet Battery Harnesses Ionic Gradients for Bioelectronic Implants

      Implantable Bioreactor for Kidney Cells

      Implantable Bioreactor for Kidney Cells

      Growth Factor-Loaded Microparticles Enhance 3D Bioprinted Muscle

      Growth Factor-Loaded Microparticles Enhance 3D Bioprinted Muscle

    • Nanomedicine
      Nanorobots Release Reactive Oxygen Species to Kill Fungal Biofilms

      Nanorobots Release Reactive Oxygen Species to Kill Fungal Biofilms

      Bottlebrush Nanoparticles Deliver Immunostimulatory Drugs

      Bottlebrush Nanoparticles Deliver Immunostimulatory Drugs

      Nanoparticles Deliver mRNA Therapy to the Lungs

      Nanoparticles Deliver mRNA Therapy to the Lungs

      Nanoparticles Get Lymphatic Vessels Pumping

      Nanoparticles Get Lymphatic Vessels Pumping

    • Military Medicine
      Wearable Can Take Multiple Sweat Samples

      Wearable Can Take Multiple Sweat Samples

      Wound Dressing Detects Infection, Changes Color

      Wound Dressing Detects Infection, Changes Color

      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fingertip Sensor Measures Lithium Levels in Sweat

    • Rehab
      Optical Strain Sensors for Rehab

      Optical Strain Sensors for Rehab

      Growth Factor-Loaded Microparticles Enhance 3D Bioprinted Muscle

      Growth Factor-Loaded Microparticles Enhance 3D Bioprinted Muscle

      Brain Computer Interface Decodes Speech and Facial Expressions

      Brain Computer Interface Decodes Speech and Facial Expressions

      Semi-Automated Manufacture of E-Skin Sensors

      Semi-Automated Manufacture of E-Skin Sensors

  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Log in
  • Submit PR
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS

Tropomyosin Receptor Kinase TRK Inhibitors Centered Cancer Targeted Therapy

November 1st, 2021 Kuick Research Releases

The enhanced understanding about the biology of cancer has shown that cancer is driven by a wide variety of clinically actionable alterations. An increase in the adoption of more comprehensive, clinical-grade sequencing platforms later promoted recognition in the presence of targetable genomic alterations across multiple tumor types. Increasing cancer incidences and need for more targeted therapy has led to identification of tropomyosin receptor kinases (TRK).

Tropomyosin receptor kinases A, B, and C (TRKA, TRKB, and TRKC) belong to cell surface receptor tyrosine kinases family and are encoded by the neutrotrophic receptor tyrosine kinase 1, 2, and 3 (NTRK1, NTRK2, and NTRK3) gene respectively. The TRK have shown to play a vital role in physiology, development, and function of the peripheral and central nervous systems. In addition, the activation of TRK triggers a cascade of signaling pathways including MAPK, P13K, and PLCy which have critical role in the cell proliferation, survival, and angiogenesis.

 

Global TRK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights: 

  • Research Methodology
  • Global & Regional Market Analysis
  • Global TRK Inhibitors Market Opportunity Assessment: > USD 2 Billion
  • Market & Drug Sales Insight 2020 Till 2026
  • Approved Drug In Market: 2 Drugs
  • Approved TRK Drug Patent, Price & Sales insight 2020 Till 2026
  • Future Market Assessment By Indication Till 2026
  • Ongoing Clinical Trials Assessment by Status, Phase & Region
  • Key Market Dynamics
  • Competitor Landscape

 

Download Report:

https://www.kuickresearch.com/report-trk-inhibitors-market-size-sales-growth-forecast

 

Further, research studies have shown that alterations in NTRK gene is found in majority of rare cancers including infantile fibrosarcoma, secretory carcinoma of breast and salivary glands, and others. In addition, NTRK gene fusions are also identified at lower frequencies in common cancers including non-small cell lung cancer, breast cancer, colorectal cancer, thyroid cancer, and others. Therefore, these fusions have emerged out to be important anti-tumor targets and considerable efforts have been done by researchers to design drugs which can inhibit their activity as an alternative for cancer management.

Vitrakvi (Larlotrectinib) developed by Loxo Oncology was the first TRK inhibitor approved. The drug was granted approval by US FDA in 2018 and is indicated for the treatment of adult and pediatric patients with solid tumors that have NTRK gene fusion without a known acquired resistance mutation are metastatic or where surgical resection is likely to result in severe morbidity and have no satisfactory alternative treatments or that have progressed following treatment. Following this, the drug has subsequently gained approval in other regions also.

Later, Genentech developed another TRK and anaplastic lymphoma kinase inhibitor which showed potential anti-tumor activity. Rozlytrek (Entrectinib) was granted approval in 2019 for the treatment of adult patients with non-small cell lung cancer. Furthermore, the drug was also approved for the management of adult and pediatric patients 12 years of age and older with NTRK positive solid tumors.

Since their entry into the market, these drugs have shown high penetration rates owing to their targeted nature. Their robust response has initiated several research and development activities by researchers which have led to the development of robust pipeline of drugs which are expected to enter the market in coming years. The potential next generation TRK inhibitors in pipeline are including Selitrectinib, IC723, or CHC2014. These have shown to overcome the limitations of first generation TRK inhibitors and are expected to enter the market during forecast period.

Currently, the researchers are evaluating the role of approved TRK inhibitors in other NTRK positive cancers which will further propel the growth of market. Apart from this, researchers are also evaluating the role of first generation TRK inhibitor in combination with other cancer targeting regimens including immunotherapeutic drugs, chemotherapeutic agents, and other small molecule targeting drugs. The combinational therapy combined two or more molecules which have synergistic activity, thus enhancing its efficacy in the management of cancer cell.

The major key players working in global TRK inhibitor market are Roche, AstraZeneca, Pfizer, Eli Lilly, Turning Point, and Loxo Oncology. These pharmaceutical giants have adopted strategic alliances including collaboration, partnerships, or joint ventures. The strategic alliances allow companies to share risks and rewards as well as offer opportunity to utilize each other novel technologies.  For instance in May, 2021 AUM Biosciences have entered into strategic collaboration with Handok Inc. and CMG Pharmaceutical for the worldwide (excluding Korea) development, commercialization, and manufacturing rights of CHC2014, which is highly specific and efficacious pan-TRK inhibitor.

Currently, the global TRK inhibitor market is small due to approval of two products only. However, it is expected that in forthcoming years, market will witness high growth rates owing to rapid approval of next generation TRK inhibitors and extended approval in other therapeutic conditions. In addition, coming years will witness increase in prevalence of cancer which will increase the demand of targeted therapy, thus boosting the growth of market.

US is expected to maintain a significant share in the global TRK inhibitor market owing to predominant sales of approved drugs in the region. Apart from drug approvals, the pharmaceutical companies in US have also developed several favorable reimbursement policies to ensure the uptake of drugs in the market. For instance, US government has developed Vitrakvi Co-pay program and Rozlytrek Co-pay program for help with out of pocket cost associated with the drugs. These policies reduce financial toxicity on patients and help in greater adoption of the drugs by patients in US.  In addition, Europe region is likely to drive the market during the forecast period owing to increase in prevalence of cancer and developed healthcare facilities. The rest of the world like India, Middle East, and other regions are also anticipated to grow at fast rates owing to various initiatives to aware, educate people, and raise funds for the cancer.

 

Contact:

Neeraj Chawla

Research Head

neeraj@kuickresearch.com

+91-9810410366

Sign up and submit a press release

Sponsored
Clarius L20 HD3 Receives Highest Image Quality Ranking Among Five Point-of-Care Ultrasound Devices

Clarius L20 HD3 Receives Highest Image Quality Ranking Among Five Point-of-Care Ultrasound Devices

Viral Vector Manufacturing in Gene Therapy and Vaccine Development

Health and Clean Air: Why Indoor Ventilation Matters

Health and Clean Air: Why Indoor Ventilation Matters

New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options

MedTech Outlook 2023 for Latin America Released

MedTech Outlook 2023 for Latin America Released

interviews & reviews
Refillable Device for Drug Delivery Past the Blood-Brain Barrier: Interview with Mike Maglin, CEO at CraniUS

Refillable Device for Drug Delivery Past the Blood-Brain Barrier: Interview with Mike Maglin, CEO at CraniUS

UV-Free Air Decontamination: Interview with Sorel Rothschild, VP at Quantum Innovations

UV-Free Air Decontamination: Interview with Sorel Rothschild, VP at Quantum Innovations

EarliPoint Evaluation System for ASD Diagnosis: Interview with Tom Ressemann, CEO of EarliTec Dx

EarliPoint Evaluation System for ASD Diagnosis: Interview with Tom Ressemann, CEO of EarliTec Dx

Visually Guided Uterine Biopsies in Physician’s Office: Interview with Allison London Brown, CEO of LUMINELLE

Visually Guided Uterine Biopsies in Physician’s Office: Interview with Allison London Brown, CEO of LUMINELLE

AI-Powered Pain Relief: Interview with Claire Smith, VP at Nevro

AI-Powered Pain Relief: Interview with Claire Smith, VP at Nevro

MISHA Knee Shock Absorber: Interview with Anton Clifford, CEO of Moximed

MISHA Knee Shock Absorber: Interview with Anton Clifford, CEO of Moximed

Shelf-Stable Breast Milk Powder: Interview with Dr. Vansh Langer, CEO at BBy

Shelf-Stable Breast Milk Powder: Interview with Dr. Vansh Langer, CEO at BBy

  • Subscribe
  • Contact us
  • Submit
  • About
  • Back to top
Medgadget

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.

  • About
  • Editorial policies
  • Contact
  • Terms of Service
  • Privacy
  • Submit press release
  • Advertise
© Medgadget, Inc. All rights reserved. | The Medical Revolution Will Be Blogged.
Please support this website by adding us to your whitelist in your ad blocker. Ads are what helps us bring you premium content! Thank you!
  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Email